Skip to main content
Niall McAlister

Niall McAlister

Edwards Wildman Palmer UK LLP
Partner
Search Me on: Edwards Wildman

Results for: Niall McAlister

    • London Tel +44 (0) 20 7556 4421 | Fax +44 (0) 20 7716 3651

    Edwards Wildman advises on funding new diagnostic company established to develop quick, early diagnosis for respiratory and other major diseases ...

    Niall has practised business law for over twenty years and has a wide experience of mergers and acquisitions, joint ventures and private equity and venture capital transactions. He has acted for a number of clients in the life sciences, insurance and reinsurance and financial services sectors. He has also led teams on a number of substantial cross-border transactions. He has particular experience representing life sciences clients, having advised both commercial entities and medical research charities on a range of transactions in the sector. He is recognised in directories both for his expertise as a corporate lawyer in the life sciences sector and as a charity lawyer.

    Niall is recommended for transactions and venture capital investments in the life sciences sector by the UK Legal 500 (2013 edition) which recognises his 'practical approach and deep industry understanding’.

    The London VC team supports entrepreneurs, early stage businesses and angel investors through the Firm's HIT Programme which defers legal fees for innovative business until such time as they raise significant finance or generate revenues and by offering start-up clients access to free software that enables them to write their own legal business documentation; to view please click here. We also support those that support entrepreneurs through our sponsorship and hosting of sponsoring various Angels Den events.

    Life Sciences  

    • Led a cross-border team representing a major international pharmaceutical client on its auction bid for a substantial European pharmaceutical business.

    • Led a Europe-wide team in 16 jurisdictions advising on European aspects of the buy-out of the medical imaging business of Eastman-Kodak (now called Carestream Health) and on the subsequent group restructuring.

    • Advised a global life sciences client on the disposal of its UK dialysis business.

    • Worked with the Wellcome Trust to structure, finance and complete the spin-out of Kymab Limited from its research campus at Hinxton, Cambridge. This was the first spin-out from a Wellcome Trust research centre.

    • Represented the Wellcome Trust on its joint venture with GlaxoSmithKline to build and operate a bioincubator at Stevenage Bioscience Park. The bioincubator will be the cornerstone facility on the park.

    • Advised on the charitable structure for UKCMRI Limited (now the Francis Crick Institute), a joint venture between MRC, UCL, Cancer Research UK and Wellcome Trust, which will create and operate the UK Centre for Medical Research and Innovation at Kings Cross, London, and negotiated the joint venture documentation. He also led negotiations with the Charity Commission on the structure.

    • Led the team that represented the Wellcome Trust on its issue of £550mn listed bonds, the first listed bond issuance by a UK charity. His work included the creation of a tax efficient limited partnership structure, negotiation with the Charity Commission and extensive legal research.

    • Represented the Wellcome Trust on its accelerated equity offering of a substantial shareholding in GSK.

    • Responsible for drafting and negotiating with the Charity Commission a new constitution for the Wellcome Trust.

    • Advised the corporate venture fund of a leading pharmaceutical company on a number of UK investments.

    • Advised the Wellcome Trust on a number of investments in European biotech companies.

    • Represented a number of biotech companies in fundraisings, including Syntaxin, Psynova Neurotech, Navion and Myaction.

    • Advised Imperial College London on the structuring of a “virtual merger” between the College’s faculty of medicine and associated NHS Trusts.

     

    Insurance & Reinsurance

    • Advising a global insurance company on a number of transactions, including acquisitions, reorganisations and joint ventures.

    • Conducting corporate transaction due diligence for a W&I insurer.

    • Representing a Lloyds managing agent on the outsourcing of its claims handling operations.

    • Advising insurance clients on agency arrangements and on the establishment of a corporate reinsurance vehicle.

     

    Private Equity

    • Advised HgCapital Trust, a listed investment trust, on the establishment and subsequent restructuring of a limited partnership sub-structure, as a means of aligning the interests of its investors and investment manager.

    • Advised the Wellcome Trust on the acquisition of a substantial residential property portfolio held via offshore unit trusts.

    • Represented PRICOA on its investment in the Arlington business parks business on disposal by BAE. He subsequently advised PRICOA on the sell-down of a substantial part interest to Legal & General; the restructuring of the investment first into a limited partnership and then into a unit trust; and on the ultimate disposal of its interests.

    • Led a team representing Bridgepoint Capital and LDC on the simultaneous buy-out of Trim Engineering and Mayflower Technical Services and a number of subsequent acquisitions and refinancings.

    • Represented Bridgepoint Capital on a number of buy-outs, including Instem, ELS and Molton Brown, portfolio acquisitions and subsequent disposals.

    • Advised ECM on the buy-out of Sovereign Rubber, its merger with a German company and the subsequent disposal of the merged business.
    • Advised LDC on a number of buy-outs and development capital transactions.

     

    Financial Services

    • Led a team that represented a consortium of UK banks in relation to the renegotiation of a joint venture with a leading outsource supplier in relation to cheque clearing services.

    • Advised a UK clearing bank on the acquisition of a number of vehicle leasing businesses and a joint venture with a leading international bank.

    • Advised a UK clearing bank on the establishment of a leading infrastructure fund.

    • Advised a range of banks and fund managers on investments into private equity and venture funds and on the establishment of bespoke funds and “favoured nation” structures.

     

    Retail/Consumer/Other

    • Led a team advising a leading UK retailer on a pan-European disposal programme.
    • Represented SHS Group on its takeover of Merrydown by way of scheme of arrangement.

    • Advised a leading Fortune 500 company on the acquisition of a UK services business.

    Featured Experience

    • Series C fundraising in F2G Limited by Astellas Venture Management

      In 2012, our London-based lawyers represented Astellas Venture Management, an existing investor, in relation to a Series C fundraising for F2G Ltd. F2G Ltd., a biopharmaceutical company, will use the proceeds to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. MORE

    • Sale of Cellzome to GlaxoSmithKline

      In May 2012, our lawyers represented Astellas Venture Management LLC in the sale of Cellzome, a developer of proteomics technologies, to GlaxoSmithKline. MORE

    • Series C fundraising in F2G Limited by Astellas Venture Management

      In 2012, our London-based lawyers represented Astellas Venture Management, an existing investor, in relation to a Series C fundraising for F2G Ltd. F2G Ltd., a biopharmaceutical company, will use the proceeds to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. MORE

    • Sale of Cellzome to GlaxoSmithKline

      In May 2012, our lawyers represented Astellas Venture Management LLC in the sale of Cellzome, a developer of proteomics technologies, to GlaxoSmithKline. MORE

    • Series C fundraising in F2G Limited by Astellas Venture Management

      In 2012, our London-based lawyers represented Astellas Venture Management, an existing investor, in relation to a Series C fundraising for F2G Ltd. F2G Ltd., a biopharmaceutical company, will use the proceeds to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. MORE

    • Series C fundraising in F2G Limited by Astellas Venture Management

      In 2012, our London-based lawyers represented Astellas Venture Management, an existing investor, in relation to a Series C fundraising for F2G Ltd. F2G Ltd., a biopharmaceutical company, will use the proceeds to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. MORE

    • Series C fundraising in F2G Limited by Astellas Venture Management

      In 2012, our London-based lawyers represented Astellas Venture Management, an existing investor, in relation to a Series C fundraising for F2G Ltd. F2G Ltd., a biopharmaceutical company, will use the proceeds to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. MORE

    • Sale of Cellzome to GlaxoSmithKline

      In May 2012, our lawyers represented Astellas Venture Management LLC in the sale of Cellzome, a developer of proteomics technologies, to GlaxoSmithKline. MORE

    • Series C fundraising in F2G Limited by Astellas Venture Management

      In 2012, our London-based lawyers represented Astellas Venture Management, an existing investor, in relation to a Series C fundraising for F2G Ltd. F2G Ltd., a biopharmaceutical company, will use the proceeds to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. MORE

    • Sale of Cellzome to GlaxoSmithKline

      In May 2012, our lawyers represented Astellas Venture Management LLC in the sale of Cellzome, a developer of proteomics technologies, to GlaxoSmithKline. MORE

    • Series C fundraising in F2G Limited by Astellas Venture Management

      In 2012, our London-based lawyers represented Astellas Venture Management, an existing investor, in relation to a Series C fundraising for F2G Ltd. F2G Ltd., a biopharmaceutical company, will use the proceeds to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. MORE

    • Series C fundraising in F2G Limited by Astellas Venture Management

      In 2012, our London-based lawyers represented Astellas Venture Management, an existing investor, in relation to a Series C fundraising for F2G Ltd. F2G Ltd., a biopharmaceutical company, will use the proceeds to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. MORE

    • Sale of Cellzome to GlaxoSmithKline

      In May 2012, our lawyers represented Astellas Venture Management LLC in the sale of Cellzome, a developer of proteomics technologies, to GlaxoSmithKline. MORE

    • Series C fundraising in F2G Limited by Astellas Venture Management

      In 2012, our London-based lawyers represented Astellas Venture Management, an existing investor, in relation to a Series C fundraising for F2G Ltd. F2G Ltd., a biopharmaceutical company, will use the proceeds to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. MORE

    • Sale of Cellzome to GlaxoSmithKline

      In May 2012, our lawyers represented Astellas Venture Management LLC in the sale of Cellzome, a developer of proteomics technologies, to GlaxoSmithKline. MORE

    • Series C fundraising in F2G Limited by Astellas Venture Management

      In 2012, our London-based lawyers represented Astellas Venture Management, an existing investor, in relation to a Series C fundraising for F2G Ltd. F2G Ltd., a biopharmaceutical company, will use the proceeds to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. MORE

    • Sale of Cellzome to GlaxoSmithKline

      In May 2012, our lawyers represented Astellas Venture Management LLC in the sale of Cellzome, a developer of proteomics technologies, to GlaxoSmithKline. MORE

    Besides Edwards Wildman

    Niall has played hockey (that’s field hockey) for over 35 years and still plays as much as his faltering body permits. He is a level 1 coach and has coached his club’s juniors for the last ten seasons. Otherwise, he enjoys reading, the company of his wife and children and an occasional game of cricket or golf.

    Education +-

    Courts+-

    The hiring of a lawyer is an important decision that should not be based solely on advertisements. Prior results do not guarantee a similar outcome.